This study was designed to investigate whether @entity851 factor I ( @entity442 ) excess could lead to the development of @entity1067 and/or @entity263 . Prostatic diameters and volume as well as the occurrence of @entity4623 were studied by ultrasonography in 10 untreated acromegalic @entity1 less than 40 yr of age and 10 age- and body mass index-matched healthy males. Serum GH, @entity442 , PRL, @entity251 , @entity586 , @entity1486 , and prostatic acid phosphatase levels were assessed. All @entity1 had @entity6126 , as diagnosed by low @entity251 levels, and 4 of 10 @entity1 had @entity4089 . After 1 yr of treatment with @entity2390 (0.3-0.6 mg/day), ultrasound scan and hormone parameters were repeated. The 4 hyperprolactinemic acromegalics were treated with @entity2390 and @entity9229 (1-2 mg/week) to suppress PRL levels. Symptoms due to prostatic, seminal vesicle, and/or @entity5331 or @entity3885 were experienced by neither acromegalics nor controls. Digital rectal examination revealed no occurrence of prostatic nodules or other abnormalities. Compared to healthy subjects, a remarkable increase in transversal prostatic diameter and volume was observed in acromegalics. In healthy subjects, prostate volume ranged from 15.1-21.8 mL, whereas in acromegalics it ranged from 21.8-41.8 mL. Similarly, an increased median lobe was observed. In fact, the transitional zone diameter was just detectable in 5 of 10 controls, whereas it was measurable in all acromegalics (18 +/- 1.2 vs. 2.8 +/- 0.3 mm; P < 0.001). The prevalence of periurethral calcifications was more than doubled in acromegalics (50%) compared to that in controls (20%). Treatment with @entity2390 for 1 yr produced normalization of circulating GH and @entity442 levels in 7 of 10 @entity1 . In these 7 @entity1 , ultrasound evaluation showed a significant reduction of the antero-posterior diameter (26.1 +/- 1 vs. 28.9 +/- 1.6 mm; P < 0.01), the transversal diameter (44.9 +/- 2 vs. 48 +/- 2 mm; P < 0.01), and the cranio-caudal diameter (36.5 +/- 1 vs. 41.3 +/- 1.5 mm; P < 0.001), whereas the transitional zone diameter was unchanged (16.4 +/- 1.5 vs. 17.4 +/- 1.7 mm). As a consequence, a significant decrease in prostate volume was recorded (22.1 +/- 1.1 vs. 29.8 +/- 2.5 mL; P < 0.001). Prostate volume increased in 2 of the 3 @entity1 who did not achieve normalization of GH and @entity442 after @entity2390 treatment. Finally, after treatment, serum @entity251 levels were significantly increased (from 1.5 +/- 0.3 to 3.5 +/- 0.3 microg/L), whereas @entity586 , @entity9027 , @entity2671 , @entity53 , @entity1486 were unchanged. Serum PRL levels were suppressed after @entity9229 treatment in all 4 hyperprolactinemic @entity1 throughout the study period. In conclusion, prostate enlargement occurs in young acromegalics with a higher than expected prevalence of micro- and macrocalcifications. This suggests that a careful prostate screening should be included in the work-up and follow-up of acromegalic males.

XXXX : an unknown feature of acromegaly.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinemia'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity851 :: ('MESH:D006130', 'Disease') :: ['GH and insulin-like growth'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic carcinoma'] @entity586 :: ('MESH:D013196', 'Chemical') :: ['dihydrotestosterone'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['cabergoline'] @entity5331 :: ('MESH:D014522', 'Disease') :: ['urethral disorders'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostatic hyperplasia'] @entity442 :: ('3479', 'Gene') :: ['IGF-I'] @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstruction'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['17beta-estradiol'] @entity4623 :: ('MESH:D011469', 'Disease') :: ['prostatic diseases'] @entity6126 :: ('MESH:D007006', 'Disease') :: ['secondary hypogonadism'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide'] @entity9027 :: ('MESH:D019314', 'Chemical') :: ['dehydroepiandrosterone sulfate'] @entity2671 :: ('MESH:D000735', 'Chemical') :: ['delta4-androstenedione'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen, and prostatic acid phosphatase', 'prostate-specific antigen']
@entity1067 :: (MESH:D011470,Disease) :: ['Prostatic hyperplasia']
